Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug;22(4):241-8.

Saliva: an emerging biofluid for early detection of diseases

Affiliations
Review

Saliva: an emerging biofluid for early detection of diseases

Yu-Hsiang Lee et al. Am J Dent. 2009 Aug.

Abstract

The capability to assess physiological states, detect morbidity initiation and progression, and monitor posttreatment therapeutic outcomes through a noninvasive approach is one of the most desirable goals for healthcare research and delivery. Saliva, a multi-constituent oral fluid, has high potential for the surveillance of general health and disease. To reach the above goal through saliva-based diagnostics, two prerequisites must be fulfilled: (1) discovering biomarker(s) for different diseases among the complicated components of saliva, and (2) advancing sensitivity and specificity of biomarker(s) through persistent development of technologies. Under the support and research blueprint initiated by the National Institute of Dental and Craniofacial Research (NIDCR), salivary diagnostics has not only steadily progressed with respect to accuracy and availability, but has also bridged up-to-date nanotechnology to expand the areas of application. With collective efforts over several years, saliva has been demonstrated to be a promising bodily fluid for early detection of diseases, and salivary diagnostics has exhibited tremendous potential in clinical applications. This review presents an overview of the value of saliva as a credible diagnostic tool, the discovery of salivary biomarkers, and the development of salivary diagnostics now and in the future.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement: Dr. David Wong is co-founder of RNAmeTRIX Inc., a molecular diagnostics company. Dr. Lee has no conflict of interest.

Figures

Fig. 1
Fig. 1
Mechanism of molecular transport from serum into salivary gland ducts. A. Active transport.B. Passive diffusion. C. Simple filtration. D. Acinar cells actively pump sodium ions (Na+) into the duct. E. Duct cells pump Na+ ions back into blood. F. Cell membrane. G. Pore on the cell membrane. H. Intracellular space. I. Acinar cell. (This figure was adapted from Haeckel and Hanecke with permission of Walter de Gruyter GmbH & Co. Copyrighted and used with permission of Mayo Foundation for Medical Education and Research, all rights reserved).
Fig. 2
Fig. 2
Collection of whole saliva by the Salivette (absorbent) method. (a) Saliva is collected by chewing a cotton wool swab. (b) The swab containing saliva is placed in the tube of Salivette. (c) Centrifugation of the assemblage. (d) Saliva is separated from the swab and is ready for analysis.
Fig. 3
Fig. 3
2D gel electrophoretograms of human whole saliva proteins. Proteins were separated in the 1st dimension immobilized pH gradients (IPG) followed by SDS-PAGE. Speckles were visualized by SYPRO Ruby stain. The arrows indicate five isoforms of carbonate dehydratase VI precursor. Targets of interest will be identified by subsequent MS analysis.
Fig. 4
Fig. 4
Oral Fluid NanoSensor Test (OFNASET), a point-of-care, automated, easy-to-use integrated system that will enable simultaneous, accurate, and rapid detection of multiple salivary protein and nucleic acid biomarkers.

References

    1. Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10. - PubMed
    1. Jill PC, William CK, Steven EK, David M, Jose CF, George AB, Steven MH, Mary H, David MN. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4:382–393. - PMC - PubMed
    1. Sidransky D. Nucleic acid-based methods for the detection of cancer. Sciences. 1997;278:1054–1059. - PubMed
    1. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18:65–73. - PubMed
    1. Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, Libertino JA, Summerhayes LC. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. 2003;98:737–744. - PubMed

Publication types

LinkOut - more resources